Ketamine’s Evolving Role in Addressing Treatment Resistant Depression

Ketamine, originally developed as a safer alternative to phencyclidine, has become a groundbreaking treatment in psychiatric practice. Approved by the United States Food and Drug Administration (FDA) in 1970 for its analgesic properties and ability to induce altered consciousness while preserving vital functions, ketamine gained renewed attention in the 1990s when researchers discovered its rapid and potent antidepressant effects, particularly in treatment-resistant depression. Ketamine’s mechanism of action involves blocking N-Methyl-D-Aspartate (NMDA) receptors, which leads to the release of inhibitory signals and increased glutamate levels. This cascade of events promotes neuronal growth and synaptic plasticity, both essential for its antidepressant effects. Various methods of administration have been explored, including intravenous (IV), intranasal, oral, subcutaneous, and intramuscular routes, each offering unique benefits and limitations. While IV ketamine remains the most widely used form, intranasal and sublingual formulations are increasingly popular for their improved accessibility and safety. Notably, the FDA and the European Medicines Agency (EMA) have approved intranasal S-ketamine for the treatment of resistant depression and depressive symptoms. Ketamine’s safety profile is generally favorable, with side effects that are mild, temporary, and self-limiting. However, caution is necessary for individuals with uncontrolled hypertension, cardiovascular issues, a history of psychosis, or substance abuse. Pregnant women are also advised against ketamine use, and potential interactions with other medications require careful consideration. Guidelines recommend ketamine as a third-line treatment option for resistant depression, to be considered after multiple unsuccessful antidepressant therapies. While international recommendations vary slightly, ketamine is increasingly recognized as a promising intervention for addressing the challenges of treatment-resistant depression. This review underscores the expanding role of ketamine in psychiatric care, particularly its applications in treatment- resistant depression and its potential to transform acute psychiatric emergency departments. It also sheds light on administration methods, safety considerations, and international guidelines for optimizing its use in challenging psychiatric conditions.